Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term investors. See more on GILD stock here.

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

Gilead Sciences cites strong growth in its HIV and oncology portfolios during Q2 2024. Revenue of $7.0 billion, up 6% excluding Veklury. Management maintained full-year guidance for product sales.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 ...

When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option to the need to take tablets ...

HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding expectations. Biktarvy delivered 13% growth, achieving over 50% U.S. market share, while Descovy maintained more than 40% ...

However, Gilead's Genvoya (2015), Odefsey (2016), Descovy (2016), and Biktarvy (2018) launches push patent protection into the 2030s and are boosting the firm's market share. Novel drug ...